Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Pharma company PTC Therapeutics has appointed Tuyen Ong as senior vice president, head of clinical development and translational research. 27 November 2014
The president of Japanese drug major Takeda Pharmaceutical’s (TYO: 4502) US subsidiary, Douglas Cole, has resigned, after 22 years with the company. 21 November 2014
Just a day after French pharma major Sanofi denied that the future of its chief executive was under discussion, at a board meeting convened at 8am this morning it decided unanimously to remove Christopher Viehbacher as chief executive of the company. 29 October 2014
Chris Viehbacher, chief executive of French drug major Sanofi, has urged the company’s board to clarify rumors that he is to be dismissed, according to a letter published in French business newspaper Les Echos. 28 October 2014
Belgian regenerative, protective and reconstructive therapy specialist Cardio3 Biosciences has appointed Warren Sherman as chief medical officer. 23 October 2014
UK-based inflammatory disease and cancer specialist Karus Therapeutics has appointed Simon Roitt as head of clinical development and Peter Finan as head of biology. 21 October 2014
Therapeutic antibody specialist AnaptysBio has appointed Marco Londei as chief development officer, leading the preclinical and clinical development of AnaptysBio’s proprietary antibody pipeline. 20 October 2014
German pharma company Grünenthal Group has appointed Sascha Becker as group chief financial officer, commencing in the first quarter of 2015. 20 October 2014